ClinicalTrials.gg
TerminatedNCT06113328Updated Jul 10, 2026Results posted

A Clinical Study of MK-6194 for the Treatment of Vitiligo (MK-6194-007)

A Phase 2 interventional study of MK-6194 and Placebo in Non-segmental Vitiligo, sponsored by Merck Sharp & Dohme LLC. Terminated at 68 sites in 18 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-07-10.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment

Why this study was terminated
Business Reasons

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
169
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 80 studies in Vitiligo with a site in United States — 14 open to participants now, 24 under way, 7 of them phase 3. Vitiligo · United States.

Enrollment
19th of 68
169 · median 37
Started
2023
with 9 others
Phase 2
31 of 80
6 open now
Registered
63rd of 80
by date

Among the 80 studies in Vitiligo with a site in United States, this one is the 19th largest by enrollment of the 68 interventional ones that give a count, is one of 10 that started in 2023, is one of 31 in phase 2, and was the 63rd registered.

Vitiligo

343 studies on the registry are indexed under Vitiligo; 96 are open to participants now.

Browse Vitiligo studies →

Open to participants now

14 of the 80 studies in Vitiligo with a site in United States are open now. Recruiting first, the newest first:

9 more — sign in →

All 14 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 48 Vitiligo studies recruiting now, 13 (27%) set no upper age limit and 29 (60%) stop at 75 or younger; 18 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 80 studies in Vitiligo with a site in United States, or all of them as a file.
02

Study summary

Researchers are looking for a new way to treat people with non-segmental vitiligo (NSV). The goal of this study is to learn about the safety of MK-6194 and how well people tolerate it. Researchers also want to learn if people who take MK-6194 have more of a decrease in the amount of vitiligo on their face compared to people who take placebo.

Read the detailed description

This study will consist of two periods. During the Double-Blind Treatment Period, participants will be randomized to one of three treatment arms to receive MK-6194 at one of two doses or placebo and will be evaluated for safety and efficacy. Participants who complete this period may enter the Blinded Extension Period, during which MK-6194 treatment will continue or placebo recipients will be re-randomized to MK-6194 at one of two doses.

03

Conditions studied

  • Non-segmental Vitiligo

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has a clinical diagnosis of non-segmental vitiligo
  • Has non-segmental vitiligo with disease duration of at least 6 months
  • Has depigmentation contributing to Facial Vitiligo Area Scoring Index (F-VASI) ≥ 0.3 at screening and baseline
  • Has depigmented facial body surface area (BSA) ≥0.3% at screening and baseline
  • Has Total Vitiligo Area Scoring Index (T-VASI) ≥4 at screening and baseline
  • Has total body vitiligo area ≥4% at screening and baseline excluding hands and feet involvement

Exclusion criteria

Exclusion Criteria:

  • Has segmental vitiligo
  • Has ≥50% leukotrichia on face or body
  • Has any other dermatological diseases that would interfere with vitiligo assessments
  • Has history of or current inflammatory condition other than vitiligo that, in the opinion of the investigator, could interfere with the evaluation of vitiligo
  • Has a known systemic to interleukin 2 (IL-2), or modified IL-2 including MK-6194, or its inactive ingredients
  • Has an active or infection requiring hospitalization or treatment with IV anti-infectives within 4 weeks prior to Randomization, or oral/intramuscular anti-infective therapy within 2 weeks prior to Randomization
  • Has symptomatic heart failure ( class III or IV) or myocardial infarction or unstable angina pectoris within 6 months prior to Screening
  • Has a severe chronic pulmonary disease requiring oxygen therapy
  • Has a transplanted organ, which requires continued
  • Has a history of any , except for successfully treated non-melanoma skin cancer or localized carcinoma in situ of the cervix
  • Has evidence of active tuberculosis (TB), latent TB, or inadequately treated TB
  • Has confirmed or suspected COVID-19 infection
  • Has history of drug or alcohol abuse within 6 months prior to Screening
  • Has had major surgery within 3 months prior to Screening OR has a major surgery planned during the study
  • Has had an inadequate response (as evaluated by a dermatologist or local physician specialist equivalent) to previous treatment with a Janus kinase inhibitor (JAKi) after an appropriate treatment duration (eg, ≥12 weeks)
  • Has received prohibited medications within protocol-specified timeframes prior to Randomization
  • Has participated in another clinical study within 4 weeks prior to Randomization
  • Has donated or lost ≥1 unit of blood (approximately 500 mL) within 4 weeks prior to the Screening Visit
  • Has received cosmetic or other procedures that could interfere with evaluation of vitiligo during the study
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
169 participants (actual)

Study arms

  • Experimental
    MK-6194 3 mg Q2W

    Participants will receive subcutaneous (SC) MK-6194 3 mg every two weeks (Q2W).

    Biological: MK-6194

  • Experimental
    MK-6194 3 mg Q4W

    Participants will receive SC MK-6194 3 mg every four weeks (Q4W).

    Biological: MK-6194

  • Placebo comparator
    Placebo

    Participants will receive SC Placebo Q2W.

    Drug: Placebo

  • Experimental
    MK-6194 3 mg Q2W (double-blind) / MK-6194 3 mg Q2W (extension)

    After completing 24 weeks of treatment with SC MK-6194 administered 3 mg Q2W in the Double-Blind Treatment Period, participants will continue to receive SC MK-6194 3 mg Q2W in the Blinded Extension Period.

    Biological: MK-6194

  • Experimental
    MK-6194 3 mg Q4W (double-blind) / MK-6194 3 mg Q4W (extension)

    After completing 24 weeks of treatment with SC MK-6194 administered 3 mg Q4W in the Double-Blind Treatment Period, participants will continue to receive SC MK-6194 3 mg Q4W in the Blinded Extension Period.

    Biological: MK-6194

  • Experimental
    Placebo (double-blind)/ MK-6194 3 mg Q2W (extension)

    After completing 24 weeks of treatment with SC Placebo administered Q2W in the Double-Blind Treatment Period, participants will be re-randomized to receive SC MK-6194 3 mg Q2W in the Blinded Extension Period.

    Biological: MK-6194

  • Experimental
    Placebo (double-blind)/ MK-6194 3 mg Q4W (extension)

    After completing 24 weeks of treatment with SC Placebo administered Q2W in the Double-Blind Treatment Period, participants will be re-randomized to receive SC MK-6194 3 mg Q4W in the Blinded Extension Period.

    Biological: MK-6194

Interventions

  • BiologicalMK-6194

    MK-6194 administered subcutaneously (SC)

  • DrugPlacebo

    Placebo comparator to MK-6194 administered SC

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in Facial Vitiligo Area Scoring Index (F-VASI) at Week 24

    VASI is a validated scoring method that measures the extent and severity of vitiligo depigmentation. The F-VASI measures vitiligo involvement of the facial area. For facial lesions, size is estimated using fingertip units (FTU), fingers, or thumbs: 1 FTU is approximately 0.03% body surface area (BSA), while a finger or thumb is approximately 0.1% BSA. Depigmentation at each site is graded to the nearest percentage: 0%, 10%, 25%, 50%, 75%, 90%, or 100%. F-VASI is calculated by multiplying the area (in FTUs) by the depigmentation percentage for each facial site and summing the values. Scores range from 0 to approximately 3.5, with higher scores indicating greater vitiligo involvement of the facial area (more severe depigmentation). Percent change from baseline calculated as post-baseline value minus baseline value, divided by baseline value and multiplied by 100%. Longitudinal data analysis (LDA) model-based least squares mean (LSM) percent change from baseline to Week 24 was reported.

    Time frame: Baseline and Week 24

  2. Number of Participants Who Experienced an Adverse Event (AE)

    An AE is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention whether or not considered related to the study intervention. The number of participants who experienced an AE is reported.

    Time frame: Up to approximately 28 weeks

  3. Number of Participants Who Discontinued Study Treatment Due to an AE

    An AE is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention whether or not considered related to the study intervention. The number of participants who discontinued study treatment due to an AE is reported here.

    Time frame: Up to approximately 24 weeks

Secondary outcomes

  1. Percent Change From Baseline in Total Vitiligo Area Scoring Index (T-VASI) at Week 24

    T-VASI is a validated scoring method that measures the extent and severity of vitiligo across the entire body. The body is divided into six regions: head/neck, hands, upper extremities, trunk, lower extremities, and feet. One hand unit (palm and fingers together) represents 1% of BSA. Depigmentation for each region is graded to the nearest percentage: 0%, 10%, 25%, 50%, 75%, 90%, or 100%. For regions with multiple lesions, percentages are averaged. The T-VASI score is calculated by multiplying the area (in hand units) by the depigmentation percentage for each region and summing all regions. Scores range from 0 to 100, with 0 indicating no vitiligo and 100 indicating complete body involvement. Percent change from baseline calculated as post-baseline value minus baseline value, divided by baseline value and multiplied by 100%. LDA model-based LSM percent change from baseline to Week 24 was reported.

    Time frame: Baseline and Week 24

07

Results

Posted Mar 17, 2026

Participant flow

Double-Blind Treatment Period
Participant flow — Double-Blind Treatment Period
MilestoneMK-6194 3 mg Q2WMK-6194 3 mg Q4WPlaceboMK-6194 3 mg Q2W (Double-blind) / MK-6194 3 mg Q2W (Extension)MK-6194 3 mg Q4W (Double-blind) / MK-6194 3 mg Q4W (Extension)Placebo (Double-blind)/ MK-6194 3 mg Q2W (Extension)Placebo (Double-blind)/ MK-6194 3 mg Q4W (Extension)
Started5755570000
Completed3445530000
Not completed231040000
Withdrew: Lost to follow-up1000000
Withdrew: Physician decision4300000
Withdrew: Withdrawal by subject12440000
Withdrew: Other6300000
Blinded Extension Period
Participant flow — Blinded Extension Period
MilestoneMK-6194 3 mg Q2WMK-6194 3 mg Q4WPlaceboMK-6194 3 mg Q2W (Double-blind) / MK-6194 3 mg Q2W (Extension)MK-6194 3 mg Q4W (Double-blind) / MK-6194 3 mg Q4W (Extension)Placebo (Double-blind)/ MK-6194 3 mg Q2W (Extension)Placebo (Double-blind)/ MK-6194 3 mg Q4W (Extension)
Started00034432726
Completed00017251316
Not completed00017181410
Withdrew: Lost to follow-up0001200
Withdrew: Physician decision0002010
Withdrew: Site terminated by sponsor0000010
Withdrew: Study terminated by sponsor000121277
Withdrew: Withdrawal by subject0002341
Withdrew: Other0000112

Outcome measures

PrimaryPercent Change From Baseline in Facial Vitiligo Area Scoring Index (F-VASI) at Week 24

VASI is a validated scoring method that measures the extent and severity of vitiligo depigmentation. The F-VASI measures vitiligo involvement of the facial area. For facial lesions, size is estimated using fingertip units (FTU), fingers, or thumbs: 1 FTU is approximately 0.03% body surface area (BSA), while a finger or thumb is approximately 0.1% BSA. Depigmentation at each site is graded to the nearest percentage: 0%, 10%, 25%, 50%, 75%, 90%, or 100%. F-VASI is calculated by multiplying the area (in FTUs) by the depigmentation percentage for each facial site and summing the values. Scores range from 0 to approximately 3.5, with higher scores indicating greater vitiligo involvement of the facial area (more severe depigmentation). Percent change from baseline calculated as post-baseline value minus baseline value, divided by baseline value and multiplied by 100%. Longitudinal data analysis (LDA) model-based least squares mean (LSM) percent change from baseline to Week 24 was reported.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · Percent change
Percent Change From Baseline in Facial Vitiligo Area Scoring Index (F-VASI) at Week 24
Percent changeMK-6194 3 mg Q2WMK-6194 3 mg Q4WPlacebo
Percent Change From Baseline in Facial Vitiligo Area Scoring Index (F-VASI) at Week 24-4.55 (-16.79 to 7.68)-12.13 (-24.29 to 0.03)-4.01 (-15.70 to 7.69)
Statistical analysis
  • MK-6194 3 mg Q2W vs Placebo · Longitudinal Data Analysis Model · p = 0.949 · Mean difference (final values): -0.55 · 95% CI -17.47 to 16.38
  • MK-6194 3 mg Q4W vs Placebo · Longitudinal Data Analysis Model · p = 0.343 · Mean difference (final values): -8.12 · 95% CI -24.99 to 8.75
  • MK-6194 3 mg Q2W vs MK-6194 3 mg Q4W · Mean difference (final values): 7.58 · 95% CI -9.67 to 24.82
PrimaryNumber of Participants Who Experienced an Adverse Event (AE)

An AE is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention whether or not considered related to the study intervention. The number of participants who experienced an AE is reported.

Time frame:
Up to approximately 28 weeks
Reported as:
Count of participants · Participants
Number of Participants Who Experienced an Adverse Event (AE)
ParticipantsMK-6194 3 mg Q2WMK-6194 3 mg Q4WPlacebo
Number of Participants Who Experienced an Adverse Event (AE)514744
PrimaryNumber of Participants Who Discontinued Study Treatment Due to an AE

An AE is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention whether or not considered related to the study intervention. The number of participants who discontinued study treatment due to an AE is reported here.

Time frame:
Up to approximately 24 weeks
Reported as:
Count of participants · Participants
Number of Participants Who Discontinued Study Treatment Due to an AE
ParticipantsMK-6194 3 mg Q2WMK-6194 3 mg Q4WPlacebo
Number of Participants Who Discontinued Study Treatment Due to an AE951
SecondaryPercent Change From Baseline in Total Vitiligo Area Scoring Index (T-VASI) at Week 24

T-VASI is a validated scoring method that measures the extent and severity of vitiligo across the entire body. The body is divided into six regions: head/neck, hands, upper extremities, trunk, lower extremities, and feet. One hand unit (palm and fingers together) represents 1% of BSA. Depigmentation for each region is graded to the nearest percentage: 0%, 10%, 25%, 50%, 75%, 90%, or 100%. For regions with multiple lesions, percentages are averaged. The T-VASI score is calculated by multiplying the area (in hand units) by the depigmentation percentage for each region and summing all regions. Scores range from 0 to 100, with 0 indicating no vitiligo and 100 indicating complete body involvement. Percent change from baseline calculated as post-baseline value minus baseline value, divided by baseline value and multiplied by 100%. LDA model-based LSM percent change from baseline to Week 24 was reported.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · Percent Change
Percent Change From Baseline in Total Vitiligo Area Scoring Index (T-VASI) at Week 24
Percent ChangeMK-6194 3 mg Q2WMK-6194 3 mg Q4WPlacebo
Percent Change From Baseline in Total Vitiligo Area Scoring Index (T-VASI) at Week 24-1.69 (-11.02 to 7.65)-9.08 (-18.24 to 0.08)0.78 (-7.77 to 9.34)
Statistical analysis
  • MK-6194 3 mg Q2W vs Placebo · Mean difference (final values): -2.47 · 95% CI -15.13 to 10.19
  • MK-6194 3 mg Q4W vs Placebo · Mean difference (final values): -9.87 · 95% CI -22.44 to 2.67
  • MK-6194 3 mg Q2W vs MK-6194 3 mg Q4W · Mean difference (final values): 7.40 · 95% CI -5.68 to 20.47

Adverse events

Collected over Up to approximately 61 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
MK-6194 3 mg Q2W0/57 (0%)3/57 (5.3%)48/57 (84.2%)
MK-6194 3 mg Q4W0/55 (0%)3/55 (5.5%)43/55 (78.2%)
Placebo0/57 (0%)0/57 (0%)34/57 (59.6%)
MK-6194 3 mg Q2W (Double-blind) / MK-6194 3 mg Q2W (Extension)0/34 (0%)0/34 (0%)19/34 (55.9%)
MK-6194 3 mg Q4W (Double-blind) / MK-6194 3 mg Q4W (Extension)0/43 (0%)0/43 (0%)27/43 (62.8%)
Placebo (Double-blind) / MK-6194 3 mg Q2W (Extension)0/27 (0%)0/27 (0%)21/27 (77.8%)
Placebo (Double-blind) / MK-6194 3 mg Q4W (Extension)0/26 (0%)1/26 (3.8%)21/26 (80.8%)
Most frequent serious events
Most frequent serious events
EventMK-6194 3 mg Q2WMK-6194 3 mg Q4WPlaceboMK-6194 3 mg Q2W (Double-blind) / MK-6194 3 mg Q2W (Extension)MK-6194 3 mg Q4W (Double-blind) / MK-6194 3 mg Q4W (Extension)Placebo (Double-blind) / MK-6194 3 mg Q2W (Extension)Placebo (Double-blind) / MK-6194 3 mg Q4W (Extension)
Cartilage injuryInjury, poisoning and procedural complications0/570/550/570/340/430/271/26
DiarrhoeaGastrointestinal disorders0/571/550/570/340/430/270/26
AppendicitisInfections and infestations0/571/550/570/340/430/270/26
Tendon ruptureInjury, poisoning and procedural complications0/571/550/570/340/430/270/26
Injection site rashGeneral disorders1/570/550/570/340/430/270/26
Hepatic enzyme increasedInvestigations1/570/550/570/340/430/270/26
Rash papularSkin and subcutaneous tissue disorders1/570/550/570/340/430/270/26
Most frequent other events
Showing 10 of 37
Most frequent other events
EventMK-6194 3 mg Q2WMK-6194 3 mg Q4WPlaceboMK-6194 3 mg Q2W (Double-blind) / MK-6194 3 mg Q2W (Extension)MK-6194 3 mg Q4W (Double-blind) / MK-6194 3 mg Q4W (Extension)Placebo (Double-blind) / MK-6194 3 mg Q2W (Extension)Placebo (Double-blind) / MK-6194 3 mg Q4W (Extension)
Injection site reactionGeneral disorders18/5712/551/578/348/434/2712/26
Injection site erythemaGeneral disorders19/5723/551/575/3413/432/276/26
NasopharyngitisInfections and infestations5/571/5513/570/345/433/271/26
HeadacheNervous system disorders10/578/553/570/341/430/270/26
Injection site pruritusGeneral disorders9/576/551/572/347/431/273/26
PruritusSkin and subcutaneous tissue disorders5/572/552/571/343/434/271/26
ArthralgiaMusculoskeletal and connective tissue disorders8/574/554/571/342/430/270/26
Injection site swellingGeneral disorders3/575/550/572/346/430/270/26
Injection site painGeneral disorders2/577/552/570/343/430/271/26
Eosinophil count increasedInvestigations7/574/550/572/344/431/271/26

Baseline characteristics

Age, Continuous
Age, Continuous(Years)MK-6194 3 mg Q2WMK-6194 3 mg Q4WPlaceboTotal
Mean45.3 ± 12.149.9 ± 12.046.4 ± 14.647.2 ± 13.0
Age, Customized
Age, Customized(Participants)MK-6194 3 mg Q2WMK-6194 3 mg Q4WPlaceboTotal
Adults (between 18 and 64 years)554751153
From 65 to 84 years28616
Sex: Female, Male
Sex: Female, Male(Participants)MK-6194 3 mg Q2WMK-6194 3 mg Q4WPlaceboTotal
Female35273092
Male22282777
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)MK-6194 3 mg Q2WMK-6194 3 mg Q4WPlaceboTotal
Hispanic or Latino23151957
Not Hispanic or Latino313537103
Unknown or Not Reported3519
Race (NIH/OMB)
Race (NIH/OMB)(Participants)MK-6194 3 mg Q2WMK-6194 3 mg Q4WPlaceboTotal
American Indian or Alaska Native65314
Asian87823
Native Hawaiian or Other Pacific Islander0000
Black or African American37212
White343440108
More than one race52310
Unknown or Not Reported1012
Vitiligo Status (Stable vs Active)
Vitiligo Status (Stable vs Active)(Participants)MK-6194 3 mg Q2WMK-6194 3 mg Q4WPlaceboTotal
Stable29283087
Active28272782
Previous JAK Inhibitor Exposure (Yes vs. No)
Previous JAK Inhibitor Exposure (Yes vs. No)(Participants)MK-6194 3 mg Q2WMK-6194 3 mg Q4WPlaceboTotal
Yes13111236
No444445133
08

Study locations

68 sites
  • Cahaba Dermatology & Skin Health Center ( Site 0127)
    Birmingham, Alabama 35244, United States
  • Burke Pharmaceutical Research ( Site 0124)
    Hot Springs, Arkansas 71913, United States
  • The Vitiligo & Pigmentation Institute of Southern California ( Site 0115)
    Los Angeles, California 90036, United States
  • Indiana University Health University Hospital-Indiana University School of Medicine, Department of (
    Indianapolis, Indiana 46202, United States
  • Dawes Fretzin Clinical Research Group, LLC ( Site 0106)
    Indianapolis, Indiana 46250, United States
  • Metro Boston Clinical Partners ( Site 0110)
    Brighton, Massachusetts 02135, United States
  • Hamzavi Dermatology - Canton ( Site 0101)
    Canton, Michigan 48187, United States
  • Remington Davis Clinical Research-Outpatient ( Site 0104)
    Columbus, Ohio 43215, United States
  • Medical University of South Carolina-Dermatology Research ( Site 0114)
    Charleston, South Carolina 29425, United States
  • International Clinical Research - Tennessee LLC ( Site 0120)
    Murfreesboro, Tennessee 37130, United States
  • Progressive Clinical Research ( Site 0108)
    San Antonio, Texas 78213, United States
  • Virginia Clinical Research, Inc. ( Site 0109)
    Norfolk, Virginia 23502, United States
  • Dermatology Specialists of Spokane ( Site 0126)
    Spokane, Washington 99202, United States
  • Psoriahue ( Site 0205)
    Ciudad Autonoma de Buenos Aires, Buenos Aires C1425DKG, Argentina
  • Stat Research S.A. ( Site 0204)
    Buenos Aires, Buenos Aires F.D. C1023AAB, Argentina
  • Centro de Investigaciones Metabólicas (CINME)-Dermatology ( Site 0203)
    Buenos Aires, Buenos Aires F.D. C1027AAP, Argentina
  • Instituto Medico Strusberg ( Site 0208)
    Córdoba, Córdoba Province X5000EDC, Argentina
  • Hospital Aleman-Dermatologia ( Site 0209)
    Buenos Aires, C1118AAT, Argentina
  • Paratus Clinical Research Woden ( Site 1703)
    Phillip, Australian Capital Territory 2606, Australia
  • Westmead Hospital-Dermatology ( Site 1701)
    Westmead, New South Wales 2145, Australia
  • Skin Health Institute Inc.-Trials ( Site 1702)
    Carlton, Victoria 3053, Australia
  • Sinclair Dermatology ( Site 1704)
    Melbourne, Victoria 3002, Australia
  • UZ Gent ( Site 0604)
    Ghent, Oost-Vlaanderen 9000, Belgium
  • UZ Leuven ( Site 0601)
    Leuven, Vlaams-Brabant 3000, Belgium
  • Enverus Medical Research ( Site 0006)
    Surrey, British Columbia V3V 0C6, Canada
  • Diex Recherche Quebec Inc. ( Site 0008)
    Québec, Quebec G1V 4T3, Canada
  • Centre de Recherche Dermatologique du Quebec metropolitain ( Site 0002)
    Québec, Quebec G1V 4X7, Canada
  • Diex Recherche sherbrooke Inc. ( Site 0007)
    Sherbrooke, Quebec J1L 0H8, Canada
  • Dermisur ( Site 0305)
    Osorno, Los Lagos Region 5310644, Chile
  • Clinical Research Chile SpA ( Site 0304)
    Valdivia, Los Ríos Region 5110683, Chile
  • Clinica Dermacross ( Site 0301)
    Santiago, Region M. de Santiago 7640881, Chile
  • Pontificia Universidad Catolica de Chile-CICUC ( Site 0308)
    Santiago, Region M. de Santiago 8330034, Chile
  • Centro Internacional de Estudios Clinicos (CIEC) ( Site 0302)
    Santiago, Region M. de Santiago 8420383, Chile
  • CliniSalud ( Site 0401)
    Envigado, Antioquia 055422, Colombia
  • IPS SURA San Diego ( Site 0408)
    Medellín, Antioquia 50016, Colombia
  • Centro Integral de Reumatología del Caribe ( Site 0405)
    Barranquilla, Atlántico 080002, Colombia
  • Healthy Medical Center S.A.S ( Site 0403)
    Zipaquirá, Cundinamarca 250252, Colombia
  • Fundación Valle del Lili ( Site 0412)
    Cali, Valle del Cauca Department 760032, Colombia
  • Centre Hospitalier Universitaire de Nice - Hôpital l'Archet ( Site 0803)
    Nice, Alpes-Maritimes 06202, France
  • CHU de Bordeaux Hop St ANDRE ( Site 0804)
    Bordeaux, Aquitaine 33075, France
  • Hôpital Edouard Herriot ( Site 0802)
    Lyon, Auvergne-Rhône-Alpes 69003, France
  • HENRI MONDOR HOSPITAL ( Site 0801)
    Créteil, Val-de-Marne 94000, France
  • Universitaetsklinikum Erlangen-Hautklinik Studienambulanz ( Site 0905)
    Erlangen, Bavaria 91054, Germany
  • Universitätsklinikum Münster-Hautklinik ( Site 0904)
    Münster, North Rhine-Westphalia 48149, Germany
  • Charité Universitaetsmedizin Berlin - Campus Mitte ( Site 0901)
    Berlin, 10117, Germany
  • Rambam Health Care Campus-Dermatology ( Site 1002)
    Haifa, 3109601, Israel
  • Sheba Medical Center-Dermatology ( Site 1001)
    Ramat Gan, 5265601, Israel
  • Nagoya City University Hospital-Dermatology ( Site 2002)
    Nagoya, Aichi-ken 467-8602, Japan
  • Osaka University Hospital ( Site 2004)
    Suita, Osaka 565-0871, Japan
  • Tokyo Medical University Hospital ( Site 2001)
    Shinjuku-ku, Tokyo 160-0023, Japan
  • Cryptex Investigación Clínica S.A. de C.V. ( Site 0515)
    Cuauhtémoc, Ciudad de México, Mexico City 06100, Mexico
  • Unidad biomedica avanzada monterrey-Clinical Trials ( Site 0504)
    Monterrey, Nuevo León 64460, Mexico
  • Centro de Atención e Investigación Clínica ( Site 0507)
    Aguascalientes, 20129, Mexico
  • Amsterdam UMC, locatie AMC-Dermatology ( Site 1101)
    Amsterdam, North Holland 1105 AZ, Netherlands
  • Inha University Hospital ( Site 1992)
    Incheon, 22332, South Korea
  • Seoul National University Hospital-Dermatology ( Site 1991)
    Seoul, 03080, South Korea
  • Severance Hospital, Yonsei University Health System-Department of Dermatology ( Site 1993)
    Seoul, 03722, South Korea
  • Hospital Universitario Puerta del Mar ( Site 1302)
    Cadiz, Andalusia 11009, Spain
  • Hospital Universitari de Bellvitge-Dermatology ( Site 1307)
    L'Hospitalet de Llobregat, Barcelona 08907, Spain
  • Clinica Universidad de Navarra ( Site 1305)
    Madrid, Madrid, Comunidad de 28027, Spain
  • Cantonal Hospital St.Gallen ( Site 1402)
    Sankt Gallen, Canton of St. Gallen 9007, Switzerland
  • UniversitätsSpital Zürich ( Site 1401)
    Zurich, Canton of Zurich 8091, Switzerland
  • Hacettepe Universite Hastaneleri-Dermatology ( Site 1501)
    Altindağ, Ankara 06230, Turkey (Türkiye)
  • Ankara Bilkent Şehir Hastanesi-Dermatology ( Site 1502)
    Ankara, 06800, Turkey (Türkiye)
  • Erciyes Universitesi Tıp Fakultesi Hastaneleri-Dermatology and Venereology ( Site 1506)
    Kayseri, 38039, Turkey (Türkiye)
  • Royal London Hospital-Dermatology Research Unit ( Site 1605)
    London, England E1 1BB, United Kingdom
  • Queen Elizabeth Hospital Birmingham ( Site 1603)
    Birmingham, Warwickshire B15 2TH, United Kingdom
  • New Cross Hospital ( Site 1601)
    Wolverhampton, WV10 0QP, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2023 to primary completion in Mar 2025, 15 months.

Results were first posted in Mar 2026, 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 27, 2023
First posted
Nov 2, 2023
StartActual
Nov 27, 2023
Primary completionActual
Mar 20, 2025
CompletionActual
Jul 30, 2025
Results first posted
Mar 17, 2026
Last update
Jul 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06113328
Responsible party
Sponsor
First posted
Nov 2, 2023
Start date
Nov 27, 2023
Primary completion
Mar 20, 2025
Completion
Jul 30, 2025
Results posted
Mar 17, 2026
Last update
Jul 10, 2026

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: MK-6194

Start the discussion